☰

Irida Kastrati, Ph.D. - Publications

Affiliations: 
2009 University of Illinois at Chicago, Chicago, IL, United States 
Area:
Pharmaceutical Chemistry
Tree Info Similar researchers PubMed Report error

33 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2023 Ekyalongo RC, Flowers B, Sharma T, Zigrossi A, Zhang A, Quintanilla-Arteaga A, Singh K, Kastrati I. SELENOF Controls Proliferation and Cell Death in Breast-Derived Immortalized and Cancer Cells. Cancers. 15. PMID 37509331 DOI: 10.3390/cancers15143671  0.406
2023 Sharma T, Zhang Y, Zigrossi A, Cravatt BF, Kastrati I. Dimethyl fumarate inhibits ZNF217 and can be beneficial in a subset of estrogen receptor positive breast cancers. Breast Cancer Research and Treatment. PMID 37477798 DOI: 10.1007/s10549-023-07037-4  0.531
2023 Flowers B, Bochnacka O, Poles A, Diamond AM, Kastrati I. Distinct Roles of SELENOF in Different Human Cancers. Biomolecules. 13. PMID 36979420 DOI: 10.3390/biom13030486  0.315
2022 Semina SE, Alejo LH, Chopra S, Kansara NS, Kastrati I, Sartorius CA, Frasor J. Identification of a novel ER-NFĸB-driven stem-like cell population associated with relapse of ER+ breast tumors. Breast Cancer Research : Bcr. 24: 88. PMID 36482488 DOI: 10.1186/s13058-022-01585-1  0.467
2022 Flowers B, Poles A, Kastrati I. Selenium and breast cancer - An update of clinical and epidemiological data. Archives of Biochemistry and Biophysics. 732: 109465. PMID 36379313 DOI: 10.1016/j.abb.2022.109465  0.392
2022 Zigrossi A, Hong LK, Ekyalongo RC, Cruz-Alvarez C, Gornick E, Diamond AM, Kastrati I. SELENOF is a new tumor suppressor in breast cancer. Oncogene. 41: 1263-1268. PMID 35082382 DOI: 10.1038/s41388-021-02158-w  0.434
2020 Kastrati I, Joosten SEP, Semina SE, Alejo LH, Brovkovych SD, Stender JD, Horlings HM, Kok M, Alarid ET, Greene GL, Linn SC, Zwart W, Frasor J. The NFκB pathway promotes tamoxifen tolerance and disease recurrence in estrogen receptor positive breast cancers. Molecular Cancer Research : McR. PMID 32245803 DOI: 10.1158/1541-7786.Mcr-19-1082  0.586
2019 Kastrati I, Semina S, Gordon B, Smart E. Insights into how phosphorylation of estrogen receptor at serine 305 modulates tamoxifen activity in breast cancer. Molecular and Cellular Endocrinology. 483: 97-101. PMID 30659843 DOI: 10.1016/J.Mce.2019.01.014  0.591
2018 Kastrati I, Brovkovych SD, Stender JD, Alarid ET, Frasor J. Abstract 5242: NFĸB pathway activation is a key determinant of tamoxifen tolerance and recurrence in breast cancer Cancer Research. 78: 5242-5242. DOI: 10.1158/1538-7445.Am2018-5242  0.584
2018 Smart E, Kastrati I, Frasor J. Abstract 2158: Inhibition of NFkB restores tamoxifen responsiveness in resistant estrogen receptor positive breast cancer in a syngeneic mouse model Cancer Research. 78: 2158-2158. DOI: 10.1158/1538-7445.Am2018-2158  0.575
2017 El-Shennawy L, Dubrovskyi O, Kastrati I, Danes JM, Zhang Y, Whiteley HE, Creighton CJ, Frasor J. Coactivation of estrogen receptor and IKK-β induces a dormant metastatic phenotype in ER-positive breast cancer. Cancer Research. PMID 29229606 DOI: 10.1158/0008-5472.Can-17-1686  0.549
2017 Petukhov PA, Abdelkarim H, Neelarapu R, Madriaga A, Kastrati I, Wang YT, Vaidya AS, Taha TY, Thatcher GRJ, Frasor J. Design, Synthesis, Molecular Modeling, and Biological Evaluation of Novel Amine-based Histone Deacetylase Inhibitors. Chemmedchem. PMID 29080240 DOI: 10.1002/Cmdc.201700449  0.53
2017 Kastrati I, Siklos MI, Brovkovych SD, Thatcher GR, Frasor J. A Novel Strategy to Co-target Estrogen Receptor and Nuclear Factor κB Pathways with Hybrid Drugs for Breast Cancer Therapy. Hormones & Cancer. PMID 28396978 DOI: 10.1007/S12672-017-0294-5  0.693
2017 Stender JD, Nwachukwu JC, Kastrati I, Kim Y, Strid T, Yakir M, Srinivasan S, Nowak J, Izard T, Rangarajan ES, Carlson KE, Katzenellenbogen JA, Yao XQ, Grant BJ, Leong HS, et al. Structural and Molecular Mechanisms of Cytokine-Mediated Endocrine Resistance in Human Breast Cancer Cells. Molecular Cell. 65: 1122-1135.e5. PMID 28306507 DOI: 10.1016/J.Molcel.2017.02.008  0.495
2017 Kastrati I, Delgado-Rivera L, Georgieva G, Thatcher GR, Frasor J. Synthesis and Characterization of an Aspirin-fumarate Prodrug that Inhibits NFκB Activity and Breast Cancer Stem Cells. Journal of Visualized Experiments : Jove. PMID 28190074 DOI: 10.3791/54798  0.643
2016 Srinivasan S, Nwachukwu JC, Bruno NE, Dharmarajan V, Goswami D, Kastrati I, Novick S, Nowak J, Cavett V, Zhou HB, Boonmuen N, Zhao Y, Min J, Frasor J, Katzenellenbogen BS, et al. Full antagonism of the estrogen receptor without a prototypical ligand side chain. Nature Chemical Biology. PMID 27870835 DOI: 10.1038/Nchembio.2236  0.493
2016 Kastrati I, Siklos MI, Calderon-Gierszal EL, El-Shennawy L, Georgieva G, Thayer EN, Thatcher GR, Frasor J. Dimethyl Fumarate Inhibits the Nuclear Factor κB Pathway in Breast Cancer Cells by Covalent Modification of p65 Protein. The Journal of Biological Chemistry. 291: 3639-47. PMID 26683377 DOI: 10.1074/Jbc.M115.679704  0.675
2016 Kastrati I, Siklos MI, Calderon-Gierszal EL, Thatcher GRJ, Frasor J. Abstract 4716: Dimethyl fumarate impairs breast cancer growth and inhibits the nuclear factor κB pathway in breast cancer cells by covalent modification of p65 Cancer Research. 76: 4716-4716. DOI: 10.1158/1538-7445.Am2016-4716  0.579
2015 Kastrati I, Litosh VA, Zhao S, Alvarez M, Thatcher GR, Frasor J. A novel aspirin prodrug inhibits NFκB activity and breast cancer stem cell properties. Bmc Cancer. 15: 845. PMID 26530254 DOI: 10.1186/S12885-015-1868-7  0.661
2015 Frasor J, El-Shennawy L, Stender JD, Kastrati I. NFκB affects estrogen receptor expression and activity in breast cancer through multiple mechanisms. Molecular and Cellular Endocrinology. 418: 235-9. PMID 25450861 DOI: 10.1016/J.Mce.2014.09.013  0.556
2015 Kastrati I, Canestrari E, Frasor J. PHLDA1 expression is controlled by an estrogen receptor-NFκB-miR-181 regulatory loop and is essential for formation of ER+ mammospheres Oncogene. 34: 2309-2316. PMID 24954507 DOI: 10.1038/Onc.2014.180  0.46
2015 Kastrati I, Siklos M, Litosh V, Thatcher G, Frasor J. Abstract 4497: Design and synthesis of hybrid drugs to target inflammatory pathways in breast cancer Cancer Research. 75: 4497-4497. DOI: 10.1158/1538-7445.Am2015-4497  0.677
2014 Stender JD, Kastrati I, Yakir M, Frasor J, Glass CK. Abstract LB-148: Inflammatory cytokines alter the sensitivity of breast cancer cells to endocrine treatments Cancer Research. 74. DOI: 10.1158/1538-7445.Am2014-Lb-148  0.533
2012 Kastrati I, Litosh VA, Thatcher GRJ, Frasor J. Abstract 3732: New aspirin analogs for targeted therapy of ER+ breast cancers with activated NFkB inflammatory pathway Cancer Research. 72: 3732-3732. DOI: 10.1158/1538-7445.Am2012-3732  0.592
2011 Kastrati I, Edirisinghe PD, Hemachandra LP, Chandrasena ER, Choi J, Wang YT, Bolton JL, Thatcher GR. Raloxifene and desmethylarzoxifene block estrogen-induced malignant transformation of human breast epithelial cells. Plos One. 6: e27876. PMID 22140478 DOI: 10.1371/Journal.Pone.0027876  0.663
2010 Kastrati I, Edirisinghe PD, Wijewickrama GT, Thatcher GR. Estrogen-induced apoptosis of breast epithelial cells is blocked by NO/cGMP and mediated by extranuclear estrogen receptors. Endocrinology. 151: 5602-16. PMID 20943808 DOI: 10.1210/En.2010-0378  0.633
2009 Qin Z, Kastrati I, Ashgodom RT, Lantvit DD, Overk CR, Choi Y, van Breemen RB, Bolton JL, Thatcher GR. Structural modulation of oxidative metabolism in design of improved benzothiophene selective estrogen receptor modulators. Drug Metabolism and Disposition: the Biological Fate of Chemicals. 37: 161-9. PMID 18936111 DOI: 10.1124/Dmd.108.023408  0.575
2008 Chang M, Overk CR, Kastrati I, Peng KW, Yao P, Qin ZH, Petukhov P, Bolton JL, Thatcher GR. Estrogenic activity of the equine estrogen metabolite, 4-methoxyequilenin. Advances in Experimental Medicine and Biology. 617: 601-7. PMID 18497087 DOI: 10.1007/978-0-387-69080-3_62  0.618
2007 Yu B, Dietz BM, Dunlap T, Kastrati I, Lantvit DD, Overk CR, Yao P, Qin Z, Bolton JL, Thatcher GR. Structural modulation of reactivity/activity in design of improved benzothiophene selective estrogen receptor modulators: induction of chemopreventive mechanisms. Molecular Cancer Therapeutics. 6: 2418-28. PMID 17876041 DOI: 10.1158/1535-7163.Mct-07-0268  0.664
2007 Overk CR, Peng KW, Asghodom RT, Kastrati I, Lantvit DD, Qin Z, Frasor J, Bolton JL, Thatcher GR. Structure-activity relationships for a family of benzothiophene selective estrogen receptor modulators including raloxifene and arzoxifene. Chemmedchem. 2: 1520-6. PMID 17654759 DOI: 10.1002/Cmdc.200700104  0.662
2007 Chang M, Peng KW, Kastrati I, Overk CR, Qin ZH, Yao P, Bolton JL, Thatcher GR. Activation of estrogen receptor-mediated gene transcription by the equine estrogen metabolite, 4-methoxyequilenin, in human breast cancer cells. Endocrinology. 148: 4793-802. PMID 17584965 DOI: 10.1210/En.2006-1568  0.664
2007 Qin Z, Kastrati I, Chandrasena RE, Liu H, Yao P, Petukhov PA, Bolton JL, Thatcher GR. Benzothiophene selective estrogen receptor modulators with modulated oxidative activity and receptor affinity. Journal of Medicinal Chemistry. 50: 2682-92. PMID 17489582 DOI: 10.1021/Jm070079J  0.611
2006 Clarke JL, Kastrati I, Johnston LJ, Thatcher GRJ. Photochemical reactions of thiols with organic nitrates - Oxygen atom transfer via a thionitrate Canadian Journal of Chemistry. 84: 709-719. DOI: 10.1139/V06-056  0.473
Show low-probability matches.